Loading…
Chill6 was cited for marketing an unapproved new drug and misbranded drug product through its website, making disease claims including that the beverage could lower anxiety during alcohol and benzodiazepine withdrawal, treat insomnia, PTSD, and social anxiety, and reduce cholesterol. The product contained phenibut and L-taurine, ingredients the company claimed had therapeutic benefits supported by international use and health benefits respectively. These marketing claims violated the Federal Food, Drug, and Cosmetic Act by establishing the product's intended use as a drug without FDA approval or proper drug classification.